Quick Answer
Cardiff Oncology, Inc. reported Diluted EPS of $0.69 per share (loss) for fiscal year 2025.
Cardiff Oncology, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.69 | +27.4% |
| 2024 | -$0.95 | -2.2% |
| 2023 | -$0.93 | -4.5% |
| 2022 | -$0.89 | -21.9% |
| 2021 | -$0.73 | +32.4% |
| 2020 | -$1.08 | +86.9% |
| 2018 | -$8.26 | +84.0% |
| 2017 | -$51.76 | -3678.1% |
| 2016 | -$1.37 | -13.2% |
| 2015 | -$1.21 | -37.5% |
| 2014 | -$0.88 | -25.7% |
| 2013 | -$0.70 | +21.3% |
| 2012 | -$0.89 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.17 | +32.0% | +19.0% |
| June 30, 2025 | -$0.21 | +19.2% | -5.0% |
| March 31, 2025 | -$0.20 | +9.1% | +20.0% |
| September 30, 2024 | -$0.25 | -13.6% | +3.8% |
| June 30, 2024 | -$0.26 | -4.0% | -18.2% |
| March 31, 2024 | -$0.22 | +12.0% | +0.0% |
| September 30, 2023 | -$0.22 | -10.0% | +12.0% |
| June 30, 2023 | -$0.25 | -4.2% | +0.0% |
- Cardiff Oncology, Inc. showed an increase of +27.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2012–2025 period, Cardiff Oncology, Inc.’s diluted eps has grown by 22.5% (from $0.89 per share (loss) to $0.69 per share (loss)).
- The most recent figure is from Cardiff Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: